Suscribirse

A fusion protein of flagellin and ovalbumin suppresses the TH2 response and prevents murine intestinal allergy - 30/11/11

Doi : 10.1016/j.jaci.2011.07.036 
Stefan Schülke, PhD a, Manja Burggraf, MSc b, Zoe Waibler, PhD c, Andrea Wangorsch, BSc a, Sonja Wolfheimer a, Ulrich Kalinke, PhD d, Stefan Vieths, PhD a, Masako Toda, PhD b, Stephan Scheurer, PhD a,
a Division of Allergology, Paul-Ehrlich-Institut, Langen, Germany 
b Junior Research Group “Allergy models”, Paul-Ehrlich-Institut, Langen, Germany 
c Junior Research Group “Novel vaccination strategies and early immune responses,” Paul-Ehrlich-Institut, Langen, Germany 
d Institute for Experimental Infection Research, TWINCORE–Center for Experimental and Clinical Infection Research, a joint venture between the Helmholtz Centre for Infection Research and the Medical School Hannover, Hannover, Germany 

Corresponding author: Stephan Scheurer, PhD, Paul-Ehrlich-Institut, Division of Allergology, Section Recombinant Allergen Therapeutics, Paul-Ehrlich-Str. 51-59, 63225 Langen, Germany.

Abstract

Background

The Toll-like receptor (TLR) 5 agonist flagellin is associated with immunomodulatory functions.

Objective

We sought to investigate whether Listeria monocytogenes–derived flagellin A (flaA) can modulate ovalbumin (OVA)–specific T-cell responses and prevent OVA-induced intestinal allergy.

Methods

Bone marrow–derived myeloid dendritic cells from BALB/c, C57BL/6, or TLR signaling–deficient (MyD88−/−) mice were stimulated with rOVA, rflaA, rflaA plus rOVA, or a recombinant fusion protein consisting of rflaA and rOVA (rflaA:OVA). The immunomodulating properties of rflaA plus rOVA and rflaA:OVA were investigated by means of DC–T-cell coculture with CD4+ T cells from OVA–T-cell receptor transgenic or OVA/alum-immunized mice. rflaA:OVA was applied as a prophylactic and therapeutic vaccine in a murine model of intestinal allergy.

Results

rflaA:OVA induced upregulation of TLR5 and dose-dependent IL-6 and IL-10 secretion by myeloid dendritic cells. IL-10 contributed to repressing IL-4 and IFN-γ secretion by OVA–T-cell receptor transgenic CD4+ T cells. Moreover, rflaA:OVA suppressed CD4+ T cells derived from TH2-biased mice on OVA/alum immunization. In a murine model of intestinal allergy, prophylactic vaccination with rflaA:OVA reduced T-cell activation. Protection from intestinal allergy included suppression of OVA-specific IgE while inducing OVA-specific IgG2a. Equimolar amounts of rflaA or rOVA provided alone or as a mixture did not have comparable effects. Moreover, therapeutic vaccination was shown to reduce allergic symptoms and T-cell activation in the spleen.

Conclusion

The rflaA:OVA fusion protein showed strong TLR-mediated immunomodulating capacities probably attributed by the proximity of adjuvant and allergen, leading to the prevention of intestinal allergy in a murine disease model. Therefore recombinant flaA:allergen fusion proteins are promising vaccine candidates for intervention in patients with IgE-mediated allergy.

El texto completo de este artículo está disponible en PDF.

Key words : Flagellin, Toll-like receptor 5, allergen vaccine, dendritic cell, intestinal allergy

Abbreviations used : CN, DC, EW, flaA, mDC, OVA, OVA/A, TCR, TLR, Treg


Esquema


 Supported by the DFG (SCHE637/3).
 Disclosure of potential conflict of interest: S. Vieths is an Associate at the Institute for Product Quality, Berlin, Germany; has received honoraria from the Food Allergy Resource and Research Program (Lincoln, Neb) and Fresenius Academy (Dortmund, Germany); has received research support from the German Federal Ministry of Health, the German Research Foundation, the Research Fund of the German Food Industry, Monsanto Company, Pioneer Hi-Bred International, the Food Allergy Research & Resource Program, the European Directorate for the Quality of Medicines and Health Care, and the German Federal Ministry for Education and Research; is a member of the European Academy of Allergy and Clinical Immunology (EAACI) Executive Committee; is Chairman of the International Union of Immunological Societies (IUIS) Allergen Standardization Subcommittee; is Secretary of the International Union of Immunological Societies (IUIS) Allergen Nomenclature Subcommittee; is a registered expert with the European Agency for the Evaluation of Medicinal Products and the European Pharmacopoeia Commission; is Chairman of the CEN (European Committee for Standardization) Technical Committee 275 Working Group 12 “Food Allergens”; and is a member of the German Society for Allergy and Clinical Immunology Food Allergy Working Group. The rest of the authors have declared that they have no conflict of interest.


© 2011  American Academy of Allergy, Asthma & Immunology. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 128 - N° 6

P. 1340 - décembre 2011 Regresar al número
Artículo precedente Artículo precedente
  • Salivary cortisol levels and allergy in children: The ALADDIN birth cohort
  • Fredrik Stenius, Magnus Borres, Matteo Bottai, Gunnar Lilja, Frank Lindblad, Göran Pershagen, Annika Scheynius, Jackie Swartz, Töres Theorell, Johan Alm
| Artículo siguiente Artículo siguiente
  • Escalating incidence of eosinophilic esophagitis: A 20-year prospective, population-based study in Olten County, Switzerland
  • Petr Hruz, Alex Straumann, Christian Bussmann, Pius Heer, Hans-Uwe Simon, Marcel Zwahlen, Christoph Beglinger, Alain M. Schoepfer, Swiss EoE study group

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2025 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.